文献速递脊柱关节炎其他结缔组织病

银屑病、银屑病关节炎与骨质疏松的系统评估:观察性与孟德尔随机化研究

Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study.
PubMed 文献 · Ann Rheum Dis · 2020-07-31

结果显示PsA患者eBMD较低,但校正甲氨蝶呤或环孢素治疗后关联消失,药物中介效应占63%;银屑病无关节炎者eBMD无差异,遗传决定银屑病/PsA与eBMD无关,MR分析未发现因果效应。结论:PsA对骨质疏松的影响是继发的(如药物)而非因果。

要点

  • PsA患者eBMD较低,但校正甲氨蝶呤或环孢素治疗后关联消失。
  • 药物中介效应占PsA对eBMD影响的63%。
  • 银屑病无关节炎者eBMD与对照无差异,非骨质疏松风险因素。

核心结论

  • PsA对骨质疏松的影响是继发的(如药物)而非因果。
  • 银屑病无关节炎不是骨质疏松的风险因素。

研究设计与样本

  • 采用多变量线性/逻辑回归评估银屑病/PsA与eBMD/骨质疏松关系,控制三个模型混杂因素。
  • 使用孟德尔随机化(MR)评估因果效应。

主要发现

  • PsA患者eBMD低于对照:model0 β=-0.014,p=0.0006;model1 β=-0.013,p=0.002。
  • 校正甲氨蝶呤或环孢素治疗(model2)后关联消失:β=-0.005,p=0.28。
  • 药物中介效应占PsA对eBMD影响的63%(p<2E-16)。
  • PsA患者骨量减少风险升高(model0 OR=1.27,p=0.002),校正药物治疗后消除(p=0.244)。
  • 遗传风险评分分析显示遗传决定银屑病/PsA与eBMD无关(p=0.24和p=0.88)。

关键数值与推荐

  • eBMD通过跟骨超声测量获得。
  • model0包括年龄、身高、体重、吸烟和饮酒;model1增加规律体力活动;model2增加药物治疗。
  • MR分析显示银屑病/PsA对eBMD、骨质疏松和骨折无因果效应。

临床怎么用

  • PsA患者骨密度降低可能继发于甲氨蝶呤或环孢素治疗,临床应关注药物对骨骼的影响。
  • 银屑病无关节炎患者无需因银屑病本身常规筛查骨质疏松。

局限性

  • eBMD基于跟骨超声测量,非双能X线吸收法。
  • 药物治疗分析仅涉及甲氨蝶呤或环孢素,未涵盖其他药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES AND METHODS: With 432 513 samples from UK Biobank dataset, multivariable linear/logistic regression were used to estimate the relationship between psoriasis/psoriatic arthritis (PsA) and estimated bone mineral density (eBMD)/osteoporosis, controlling for potential confounders. Here, confounders were set in three ways: model0 (including age, height, weight, smoking and drinking), model1 (model0 +regular physical activity) and model2 (model1 +medication treatments). The eBMD was derived from heel ultrasound measurement. And 4904 patients with psoriasis and 847 patients with PsA were included in final analysis. Mendelian randomisation (MR) approach was used to evaluate the causal effect between them. RESULTS: Lower eBMD were observed in patients with PsA than in controls in both model0 (β-coefficient=-0.014, p=0.0006) and model1 (β-coefficient=-0.013, p=0.002); however, the association disappeared when conditioning on treatment with methotrexate or ciclosporin (model2) (β-coefficient=-0.005, p=0.28), mediation analysis showed that 63% of the intermediary effect on eBMD was mediated by medication treatment (p<2E-16). Patients with psoriasis without arthritis showed no difference of eBMD compared with controls. Similarly, the significance of higher risk of osteopenia in patients with PsA (OR=1.27, p=0.002 in model0) could be eliminated by conditioning on medication treatment (p=0.244 in model2). Psoriasis without arthritis was not related to osteopenia and osteoporosis. The weighted Genetic Risk Score analysis found that genetically determined psoriasis/PsA were not associated with eBMD (p=0.24 and p=0.88). Finally, MR analysis showed that psoriasis/PsA had no causal effect on eBMD, osteoporosis and fracture. CONCLUSIONS: The effect of PsA on osteoporosis was secondary (eg, medication) but not causal. Under this hypothesis, psoriasis without arthritis was not a risk factor for osteoporosis.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Xia J, Xie SY, Liu KQ, et al. Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study. Ann Rheum Dis. 2020. PMID: 32737104. doi:10.1136/annrheumdis-2020-217892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。